COPENHAGEN, Denmark, March 11, 2026 (GLOBE NEWSWIRE)-- Commit Biologics ("Commit"), a biotechnology company pioneering complement system activation and backed by €21.5 million in seed financing from ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Scientists are closer to understanding how an everyday painkiller can ...
Type 1 diabetes is an autoimmune disease in which the immune system attacks the insulin-producing beta cells of the pancreas. Despite advances in glycemic control and the development of new ...
Scientists have discovered how a protein released by immune cells can switch on another part of the body’s defenses and drive ...
Recent clinical trials utilizing high doses of adeno-associated virus (AAV) vectors have highlighted a new challenge to AAV gene transfer—activation of the complement system. A new article in Human ...
Cancer treatment has developed around surgery, chemotherapy and radiation therapy. Although survival periods are growing as ...
In a study published in Science Immunology, researchers used malignant ascites—fluid that accumulates in the abdomen of some ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results